Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 3/20 | 0.45 |
| ▸ | LIPE | Q05469 | 1/20 | 0.43 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | GRM7 | Q14831 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2069944 | 1.00 | HSD11B1 (0.45) | HSD11B1LIPENOTUMTHRBSMN1; SMN2 | |
| SCHEMBL3942367 | 0.93 | HSD11B1 (0.40) | HSD11B1LIPENOTUMTHRBSMN1; SMN2 | |
| SCHEMBL3942371 | 0.93 | HSD11B1 (0.40) | HSD11B1LIPENOTUMTHRBSMN1; SMN2 | |
| SCHEMBL2073223 | 0.89 | PDE4B (0.48) | HSD11B1NOTUMSMN1; SMN2KMT2AMEN1 | |
| SCHEMBL2073320 | 0.89 | PDE4B (0.48) | HSD11B1NOTUMSMN1; SMN2KMT2AMEN1 | |
| SCHEMBL2073220 | 0.89 | PDE4B (0.48) | HSD11B1NOTUMSMN1; SMN2KMT2AMEN1 | |
| SCHEMBL2071651 | 0.89 | AVPR2 (0.47) | HSD11B1NOTUMSMN1; SMN2POLBTSHR | |
| SCHEMBL2073318 | 0.89 | PDE4B (0.48) | HSD11B1NOTUMSMN1; SMN2KMT2AMEN1 | |
| SCHEMBL2071649 | 0.89 | AVPR2 (0.47) | HSD11B1NOTUMSMN1; SMN2POLBTSHR | |
| SCHEMBL2071679 | 0.87 | POLB (0.52) | HSD11B1NOTUMSMN1; SMN2KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7897773-B2 | Urea derivatives of tropane, their preparation and their therapeutic application | SANOFI-AVENTIS (FR) | 2011-03-01 | — | — | US | disclosed |
| US-20100324084-A1 | UREA DERIVATIVES OF TROPANE, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | SANOFI-AVENTIS (FR) | 2010-12-23 | — | — | US | disclosed |
| EP-2046791-B1 | UREA DERIVATIVES OF TROPANE, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | SANOFI AVENTIS (FR) | 2010-03-24 | — | — | EP | disclosed |
| US-20090170894-A1 | UREA DERIVATIVES OF TROPANE, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | SANOFI-AVENTIS (FR) | 2009-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170894-A1 | UREA DERIVATIVES OF TROPANE, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | HSD11B1, ADRA1D, HSD17B1 | HSD11B1 1/4885LIPE 543/4885NOTUM 1364/4885 |
| US-20100324084-A1 | UREA DERIVATIVES OF TROPANE, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | HSD11B1, ADRA1D, HSD17B1 | HSD11B1 1/4885LIPE 543/4885NOTUM 1364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.